Chapter 6 Alcohols
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
EH&S COVID-19 Chemical Disinfectant Safety Information
COVID-19 CHEMICAL DISINFECTANT SAFETY INFORMATION Updated June 24, 2020 The COVID-19 pandemic has caused an increase in the number of disinfection products used throughout UW departments. This document provides general information about EPA-registered disinfectants, such as potential health hazards and personal protective equipment recommendations, for the commonly used disinfectants at the UW. Chemical Disinfectant Base / Category Products Potential Hazards Controls ● Ethyl alcohol Highly flammable and could form explosive Disposable nitrile gloves Alcohols ● ● vapor/air mixtures. ● Use in well-ventilated areas away from o Clorox 4 in One Disinfecting Spray Ready-to-Use ● May react violently with strong oxidants. ignition sources ● Alcohols may de-fat the skin and cause ● Wear long sleeve shirt and pants ● Isopropyl alcohol dermatitis. ● Closed toe shoes o Isopropyl Alcohol Antiseptic ● Inhalation of concentrated alcohol vapor 75% Topical Solution, MM may cause irritation of the respiratory tract (Ready to Use) and effects on the central nervous system. o Opti-Cide Surface Wipes o Powell PII Disinfectant Wipes o Super Sani Cloth Germicidal Wipe 201 Hall Health Center, Box 354400, Seattle, WA 98195-4400 206.543.7262 ᅵ fax 206.543.3351ᅵ www.ehs.washington.edu ● Formaldehyde Formaldehyde in gas form is extremely Disposable nitrile gloves for Aldehydes ● ● flammable. It forms explosive mixtures with concentrations 10% or less ● Paraformaldehyde air. ● Medium or heavyweight nitrile, neoprene, ● Glutaraldehyde ● It should only be used in well-ventilated natural rubber, or PVC gloves for ● Ortho-phthalaldehyde (OPA) areas. concentrated solutions ● The chemicals are irritating, toxic to humans ● Protective clothing to minimize skin upon contact or inhalation of high contact concentrations. -
Inositol Safety: Clinical Evidences
European Review for Medical and Pharmacological Sciences 2011; 15: 931-936 Inositol safety: clinical evidences G. CARLOMAGNO, V. UNFER AGUNCO Obstetrics & Gynecology Center, Rome (Italy) Abstract. – Myo-inositol is a six carbon ent required by the human cells for the growth cyclitol that contains five equatorial and one axi- and survival in the culture. In humans and other al hydroxyl groups. Myo-inositol has been classi- species, Myo-inositol can be converted to either fied as an insulin sensitizing agent and it is L- or D-chiro-inositol by epimerases. Early stud- commonly used in the treatment of the Polycys- tic Ovary Syndrome (PCOS). However, despite ies showed that inositol urinary clearance was al- its wide clinical use, there is still scarce informa- tered in type 2 diabetes patients, the next step tion on the myo-inositol safety and/or side ef- was to link impaired inositol clearance with in- fects. The aim of the present review was to sum- sulin resistance (for a review see1). Because of marize and discuss available data on the myo-in- these properties, inositol have been classified as ositol safety both in non-clinical and clinical set- “insulin sensitizing agent”2. tings. The main outcome was that only the highest In the recent years, inositol has found more dose of myo-inositol (12 g/day) induced mild and more space in the reproductive clinical prac- gastrointestinal side effects such as nausea, fla- tice3-6. Indeed, since the main therapy for Poly- tus and diarrhea. The severity of side effects did cystic Ovary Syndrome (PCOS) is the use of in- not increase with the dosage. -
Revisions to USP 31–NF 26, Second Supplement
Revisions to USP 31–NF 26, Second Supplement (published May 2008) Published April 2008 General Chapters Monographs:A–C D–N O–S T–Z Monograph Title Section Head Scientific Liaison DANTROLENE SODIUM Dissolution <711> CAPSULES PF 33(4) Pg. 645 DEHYDROACETIC ACID PF 33(4) Title Pg. 703 DEHYDROACETIC ACID PF 33(4) Chemical Info Pg. 703 DEHYDROACETIC ACID PF 33(4) Definition Pg. 703 DEHYDROACETIC ACID PF 33(4) Packaging and storage Pg. 703 DEHYDROACETIC ACID PF 33(4) USP Reference standards <11> Pg. 703 DEHYDROACETIC ACID PF 33(4) Identification Pg. 703 DEHYDROACETIC ACID PF 33(4) Heavy Metals, Method II <231> Pg. 703 DEHYDROACETIC ACID PF 33(4) Loss on drying <731> Pg. 703 DEHYDROACETIC ACID PF 33(4) Melting range, Class I <741> Pg. 703 DEHYDROACETIC ACID PF 33(4) Residue on ignition <281> Pg. 703 DEHYDROACETIC ACID PF 33(4) Assay Pg. 703 DIDANOSINE TABLETS FOR ORAL SUSPENSION PF 32(3) Pg. Title 784 DIDANOSINE TABLETS FOR ORAL SUSPENSION PF 32(3) Pg. Definition 784 file:///C|/Documents%20and%20Settings/rwt/Desktop/revisions/usp31nf26secondSupplement03.html[4/26/2011 1:18:07 PM] DIDANOSINE TABLETS FOR ORAL SUSPENSION PF 32(3) Pg. Packaging and storage 784 DIDANOSINE TABLETS FOR ORAL SUSPENSION PF 32(3) Pg. Labeling 784 DIDANOSINE TABLETS FOR ORAL SUSPENSION PF 32(3) Pg. USP Reference stadards 784 DIDANOSINE TABLETS FOR ORAL SUSPENSION PF 32(3) Pg. Identification 784 DIDANOSINE TABLETS FOR ORAL SUSPENSION PF 32(3) Pg. Uniformity of dosage units 784 DIDANOSINE TABLETS FOR ORAL SUSPENSION PF 32(3) Pg. Loss on drying 784 DIDANOSINE TABLETS FOR ORAL SUSPENSION PF 32(3) Pg. -
Excluded Drug List
Excluded Drug List The following drugs are excluded from coverage as they are not approved by the FDA ACTIVE-PREP KIT I (FLURBIPROFEN-CYCLOBENZAPRINE CREAM COMPOUND KIT) ACTIVE-PREP KIT II (KETOPROFEN-BACLOFEN-GABAPENTIN CREAM COMPOUND KIT) ACTIVE-PREP KIT III (KETOPROFEN-LIDOCAINE-GABAPENTIN CREAM COMPOUND KIT) ACTIVE-PREP KIT IV (TRAMADOL-GABAPENTIN-MENTHOL-CAMPHOR CREAM COMPOUND KIT) ACTIVE-PREP KIT V (ITRACONAZOLE-PHENYTOIN SODIUM CREAM CMPD KIT) ADAZIN CREAM (BENZO-CAPSAICIN-LIDO-METHYL SALICYLATE CRE) AFLEXERYL-LC PAD (LIDOCAINE-MENTHOL PATCH) AFLEXERYL-MC PAD (CAPSAICIN-MENTHOL TOPICAL PATCH) AIF #2 DRUG PREPERATION KIT (FLURBIPROFEN-GABAPENT-CYCLOBEN-LIDO-DEXAMETH CREAM COMPOUND KIT) AGONEAZE (LIDOCAINE-PRILOCAINE KIT) ALCORTIN A (IODOQUINOL-HYDROCORTISONE-ALOE POLYSACCHARIDE GEL) ALEGENIX MIS (CAPSAICIN-MENTHOL DISK) ALIVIO PAD (CAPSAICIN-MENTHOL PATCH) ALODOX CONVENIENCE KIT (DOXYCYCLINE HYCLATE TAB 20 MG W/ EYELID CLEANSERS KIT) ANACAINE OINT (BENZOCAINE OINT) ANODYNZ MIS (CAPSAICIN-MENTHOL DISK) APPFORMIN/D (METFORMIN & DIETARY MANAGEMENT CAP PACK) AQUORAL (ARTIFICIAL SALIVA - AERO SOLN) ATENDIA PAD (LIDOCAINE-MENTHOL PATCH) ATOPICLAIR CRE (DERMATOLOGICAL PRODUCTS MISC – CREAM) Page 1 of 9 Updated JANUARY 2017 Excluded Drug List AURSTAT GEL/CRE (DERMATOLOGICAL PRODUCTS MISC) AVALIN-RX PAD (LIDOCAINE-MENTHOL PATCH) AVENOVA SPRAY (EYELID CLEANSER-LIQUID) BENSAL HP (SALICYLIC ACID & BENZOIC ACID OINT) CAMPHOMEX SPRAY (CAMPHOR-HISTAMINE-MENTHOL LIQD SPRAY) CAPSIDERM PAD (CAPSAICIN-MENTHOL -
SAFETY DATA SHEET Isopropyl Alcohol
SAFETY DATA SHEET Isopropyl Alcohol Section 1. Identification GHS product identifier : Isopropyl Alcohol Chemical name : Isopropyl alcohol Other means of : isopropanol; 2-Propanol identification Product type : Liquid. Product use : Synthetic/Analytical chemistry. Synonym : isopropanol; 2-Propanol SDS # : 001105 Supplier's details : Airgas USA, LLC and its affiliates 259 North Radnor-Chester Road Suite 100 Radnor, PA 19087-5283 1-610-687-5253 24-hour telephone : 1-866-734-3438 Section 2. Hazards identification OSHA/HCS status : This material is considered hazardous by the OSHA Hazard Communication Standard (29 CFR 1910.1200). Classification of the : FLAMMABLE LIQUIDS - Category 2 substance or mixture EYE IRRITATION - Category 2A SPECIFIC TARGET ORGAN TOXICITY (SINGLE EXPOSURE) (Narcotic effects) - Category 3 GHS label elements Hazard pictograms : Signal word : Danger Hazard statements : May form explosive mixtures with air. Highly flammable liquid and vapor. Causes serious eye irritation. May cause drowsiness or dizziness. Precautionary statements General : Read label before use. Keep out of reach of children. If medical advice is needed, have product container or label at hand. Prevention : Wear protective gloves. Wear eye or face protection. Keep away from heat, hot surfaces, sparks, open flames and other ignition sources. No smoking. Use explosion- proof electrical, ventilating, lighting and all material-handling equipment. Use only non- sparking tools. Take precautionary measures against static discharge. Keep container tightly closed. Use only outdoors or in a well-ventilated area. Avoid breathing vapor. Wash hands thoroughly after handling. Response : IF INHALED: Remove person to fresh air and keep comfortable for breathing. Call a POISON CENTER or physician if you feel unwell. -
Bio-Butanol Production from Glycerol with Clostridium
Lin et al. Biotechnol Biofuels (2015) 8:168 DOI 10.1186/s13068-015-0352-6 RESEARCH Open Access Bio‑butanol production from glycerol with Clostridium pasteurianum CH4: the effects of butyrate addition and in situ butanol removal via membrane distillation De‑Shun Lin1, Hong‑Wei Yen2, Wei‑Chen Kao1, Chieh‑Lun Cheng1, Wen‑Ming Chen3, Chieh‑Chen Huang4 and Jo‑Shu Chang1,4,5* Abstract Background: Clostridium pasteurianum CH4 was used to produce butanol from glycerol. The performance of butanol fermentation was improved by adding butyrate as the precursor to trigger the metabolic pathway toward butanol production, and by combining this with in situ butanol removal via vacuum membrane distillation (VMD) to avoid the product inhibition arising from a high butanol concentration. 1 Results: Adding 6 g L− butyrate as precursor led to an increase in the butanol yield from 0.24 to 0.34 mol butanol 1 (mol glycerol)− . Combining VMD and butyrate addition strategies could further enhance the maximum effective 1 1 butanol concentration to 29.8 g L− , while the yield was also improved to 0.39 mol butanol (mol glycerol)− . The butanol concentration in the permeate of VMD was nearly five times higher than that in the feeding solution. Conclusions: The proposed butyrate addition and VMD in situ butanol removal strategies are very effective in enhancing both butanol titer and butanol yield. This would significantly enhance the economic feasibility of fermen‑ tative production of butanol. The VMD-based technology not only alleviates the inhibitory effect of butanol, but also markedly increases butanol concentration in the permeate after condensation, thereby making downstream process‑ ing easier and more cost-effective. -
Phenol Health and Safety Guide
C - z_ IPCS INTERNATIONAL._ PROGRAMME ON CHEMICAL SAFETY OD 341 Health and Safety Guide No. 88 .P5 94 Ph c.2 PHENOL HEALTH AND SAFETY GUIDE ' UNITED NATIONS INTERNATIONAL ENVffiONMENTPROG~E LABOUR ORGANISATION WORLD HEALTH ORGANIZATION WORLD HEALTH ORGANIZATION, GENEVA 1994 1 I) 1\ ' ~Ii>cs Other HEALTH AND SAFETY GUIDES available: (continued on inside back cover) Acrolein (No . 67, 1992) Endrin (No. 60, 1991) Acrylamide (No. 45 , 1991) Epichlorohydrin (No. 8, 1987) Acrylonitrile (No. I, 1986) Ethylene oxide (No. 16, 1988) Aldicarb (No. 64, 1991) Fenitrothion (No. 65, 1991) Aldrin and dieldrin (No. 21 , 1988) Fenvalerate (No. 34, 1989) Allethrins (No. 24, 1989) Folpet (No. 72, 1992) Amitrole (No. 85 , 1994) Formaldehyde (No. 57, 1991) Ammonia (No. 37, 1990) Heptachlor (No. 14, 1988) Arsenic compounds, inorganic, other than Hexachlorobutadiene (No. 84, 1993) arsine (No. 70, 1992) Hexachlorocyclohexanes, alpha- and Atrazine (No. 47, 1990) beta- (No. 53, 1991) Barium (No. 46 , 1991) Hexachlorocyclopentadiene (No. 63 , 1991) Benomyl (No. 81, 1993) n-Hexane (No. 59, 1991) Bentazone (No. 48, 1990) Hydrazine (No. 56, 1991) Beryllium (No. 44, 1990) Isobenzan (No. 61 , 1991) !-Butanol (No. 3, 1987) Isobutanol (No. 9, 1987) 2-Butanol (No. 4, 1987) Kelevan (No. 2, 1987) ten-Butanol (No. 7, 1987) Lindane (No. 54 , 1991) Camphechlor (No. 40, 1990) Magnetic fields (No. 27, 1990) Captafol (No. 49, 1990) Methamidophos (No. 79, 1993) Captan (No. 50, 1990) Methyl bromide (Bromomethane) (No. 86, 1994) Carbaryl (No. 78, 1993) Methyl isobutyl ketone (No. 58, 1991) Carbendazim (No. 82, 1993) Methyl parathion (No. 75, 1992) Chlordane (No. 13 , 1988) Methylene chloride (No. -
Enhanced Butanol Production by Free and Immobilized Clostridium Sp
Enhanced Butanol Production by Free and Immobilized Clostridium sp. Cells Using Butyric Acid as Co-Substrate Laili Gholizadeh This thesis comprises 30 ECTS credits and is a compulsory part in the Master of Science with a Major in Chemical Engineering – Applied Biotechnology 120 ECTS credits No. 10/2009 Title: Enhanced Butanol Production by Free and Immobilized Clostridium sp. Cells using Butyric Acid as Co-Substrate. Author: Laili Gholizadeh Baroghi (e-mail: [email protected]) Master Thesis Subject Category: Biotechnology (Bioprocess Engineering – Biofuels) University College of Borås School of Engineering SE-501 90 BORÅS Telephone: (+46) 033 435 4640 Examiner: Prof. Mohammad Taherzadeh Supervisor and Thesis Advisor: Prof. Shang–Tian Yang Supervisor Address: OSU–Ohio State University 125 Koffolt Laboratories 140 West 19th Ave. Columbus, OH 43210–1185, USA Client: Ohio State University (OSU), Chemical & Biomolecular Engineering Department Prof. Shang–Tian Yang Columbus, Ohio; USA. Date: 08–12–2009 Keywords: Bio-butanol y Acetone–Butanol–Ethanol (ABE) y ABE- fermentation y Butyric acid y Clostridium y C. acetobutylicum ATCC 824 y C. beijerinckii ATCC 55025 y C. beijerinckii BA 101 y C. beijerinckii NCIMB 8052 y Fibrous-bed Bioreactor (FBB) y Batch y Suspended cell culture y Immobilized cell system. DEDICATION I would like to dedicate this M.Sc. Thesis to my beloved Family for all their love and encouragement and for always been supportive of my choices. “I am among those who think that science has great beauty. A scientist in his laboratory is not only a technician: he is also a child placed before natural phenomena, which impress him like a fairy tale.” − Marie Curie ABSTRACT Butanol production by four different Clostridium sp. -
ETHYLENE GLYCOL: Environmental Aspects
This report contains the collective views of an international group of experts and does not necessarily represent the decisions or the stated policy of the United Nations Environment Programme, the International Labour Organisation, or the World Health Organization. Concise International Chemical Assessment Document 22 ETHYLENE GLYCOL: Environmental aspects First draft prepared by Dr S. Dobson, Institute of Terrestrial Ecology, Natural Environment Research Council, Huntingdon, United Kingdom Please note that the layout and pagination of this pdf file are not identical to those of the printed CICAD Published under the joint sponsorship of the United Nations Environment Programme, the International Labour Organisation, and the World Health Organization, and produced within the framework of the Inter-Organization Programme for the Sound Management of Chemicals. World Health Organization Geneva, 2000 The International Programme on Chemical Safety (IPCS), established in 1980, is a joint venture of the United Nations Environment Programme (UNEP), the International Labour Organisation (ILO), and the World Health Organization (WHO). The overall objectives of the IPCS are to establish the scientific basis for assessment of the risk to human health and the environment from exposure to chemicals, through international peer review processes, as a prerequisite for the promotion of chemical safety, and to provide technical assistance in strengthening national capacities for the sound management of chemicals. The Inter-Organization Programme for the Sound Management of Chemicals (IOMC) was established in 1995 by UNEP, ILO, the Food and Agriculture Organization of the United Nations, WHO, the United Nations Industrial Development Organization, the United Nations Institute for Training and Research, and the Organisation for Economic Co-operation and Development (Participating Organizations), following recommendations made by the 1992 UN Conference on Environment and Development to strengthen cooperation and increase coordination in the field of chemical safety. -
Transcription 12.01.12
Lecture 2B • 01/12/12 We covered three different reactions for converting alcohols into leaving groups. One was to turn an alcohol into an alkyl chloride, that was using thionyl chloride. Second reaction was using tosyl chloride; the primary difference between those two reactions is one of stereochemistry. An inversion of stereochemistry does occur if you use thionyl chloride, because it does affect the carbon-oxygen bond, but because forming a tosylate does not touch the carbon-oxygen bond, only the oxygen- hydrogen bond, there’s no change in stereochemistry there. We then saw phosphorus tribromide that reacts very similarly to the thionyl chloride; you get an alkyl bromide instead, but it also has inversion of configuration. The last reaction is not a new mechanism, it is just an Sn2 reaction, it’s called the Finkelstein reaction. Really this works, in a sense, off of Le Châtelier’s principle. In solution, in theory, sodium iodide can displace bromide, but sodium bromide can displace iodide, so you can have an Sn2 reaction that goes back and forth and back and forth and back and forth. Except, sodium iodide is somewhat soluble in acetone, while sodium chloride and sodium bromide are not. So, in fact, one of the things that we get out of this as a by-product is sodium bromide, which, again, is not soluble in acetone and therefore precipitates out and is no longer part of the reaction mixture, so there’s no reverse reaction possible. Because of this solubility trick, it allows this reaction to be pulled forward, which means you can get the alkyl iodide. -
A Cooked Composition of Glycerine and Hydrogenated Starch Hydrolysate and the Use Thereof As a Stabilizer for L-Aspartic Acid Sweetening Agent in Comestibles
Europaisches Patentamt 0 323 442 J> European Patent Office Publication number: A1 Office europeen des brevets EUROPEAN PATENT APPLICATION @ Application number: 89102633.8 IntCI* A 23 L 1/236 A 23 G 3/30 @ Date of filing: 27.03.86 2g) Priority: 29.03.85 US 717630 © Applicant: NABISCO BRANDS, INC. 100 DeForest Avenue East Hanover New Jersey 07936 (US) §) Date of publication of application: 05.07.89 Bulletin 89/27 @ Inventor: Carroll, Thomas J. States: BE DE FR GB IT 20-30 43rd Street g) Designated Contracting Astoria, N.Y. (US) jig) Publication number of the earlier application in Kehoe, Gary S. accordance with Art. 76 EPC: 0 196 640 10 Cross Hill Road Ridgefield, Conn. (US) @) Representative : Brauns, Hans-Adolf, Dr. rer. nat. et al Hoffmann, Eitle & Partner, Patentanwalte Arabellastrasse 4 D-8000 Munich 81 (DE) @ A cooked composition of glycerine and hydrogenated starch hydrolysate and the use thereof as a stabilizer for L-aspartic acid sweetening agent in comestibles. (g) A cooked composition of glycerine and hydrogenated starch hydrolysate having a moisture content of 10 ± 6% (W/W). Said composition can be used as a stabilizer for L-aspartic acid sweetening agent in comestibles. CM CO CM eo a. LU Bundesdruckerei Berlin EP 0 323 442 A1 Description A COOKED COMPOSITION OF GLYCERINE AND HYDROGENATED STARCH HYDROLYSATE AND THE USE THEREOF AS A STABILIZER FOR L-ASPARTIC ACID SWEETENING AGENT IN COMESTIBLES Aspartame which is used extensively in many types of sugarless foodstuffs, or other comestible products, 5 such as chewing gum, is known to readily decompose in the presence of moisture into decomposition products such as diketopiperizine which causes a significant loss in the sweetness properties of such products during their shelf lives. -
Ethylene Glycol Ingestion Reviewer: Adam Pomerlau, MD Authors: Jeff Holmes, MD / Tammi Schaeffer, DO
Pediatric Ethylene Glycol Ingestion Reviewer: Adam Pomerlau, MD Authors: Jeff Holmes, MD / Tammi Schaeffer, DO Target Audience: Emergency Medicine Residents, Medical Students Primary Learning Objectives: 1. Recognize signs and symptoms of ethylene glycol toxicity 2. Order appropriate laboratory and radiology studies in ethylene glycol toxicity 3. Recognize and interpret blood gas, anion gap, and osmolal gap in setting of TA ingestion 4. Differentiate the symptoms and signs of ethylene glycol toxicity from those associated with other toxic alcohols e.g. ethanol, methanol, and isopropyl alcohol Secondary Learning Objectives: detailed technical/behavioral goals, didactic points 1. Perform a mental status evaluation of the altered patient 2. Formulate independent differential diagnosis in setting of leading information from RN 3. Describe the role of bicarbonate for severe acidosis Critical actions checklist: 1. Obtain appropriate diagnostics 2. Protect the patient’s airway 3. Start intravenous fluid resuscitation 4. Initiate serum alkalinization 5. Initiate alcohol dehydrogenase blockade 6. Consult Poison Center/Toxicology 7. Get Nephrology Consultation for hemodialysis Environment: 1. Room Set Up – ED acute care area a. Manikin Set Up – Mid or high fidelity simulator, simulated sweat if available b. Airway equipment, Sodium Bicarbonate, Nasogastric tube, Activated charcoal, IV fluid, norepinephrine, Simulated naloxone, Simulate RSI medications (etomidate, succinylcholine) 2. Distractors – ED noise For Examiner Only CASE SUMMARY SYNOPSIS OF HISTORY/ Scenario Background The setting is an urban emergency department. This is the case of a 2.5-year-old male toddler who presents to the ED with an accidental ingestion of ethylene glycol. The child was home as the father was watching him. The father was changing the oil on his car.